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1061-77 Insulin Resistance and Survival in Chronic Heart Failure 
Wolfram Doehner, Ian F. Godsland, Mathias Rauchhaus, Piotr P. Ponikowski, Andrew J. 
Coats, Stefan D. Anker, National Heart & Lung Institute. London, United Kingdom 
Background: Impaired insulin sensitivity (Si) is a feature of chronic heart 
failure (CHF) independently of ischemic etiology. In CHF. impaired Si is 
related to abnormal energy metabolism, decreased exercise capacity and 
muscle fatigue. The relationship between presence of Insulin resistance 
(i.e. low Si) and survival in patients with CHF has not been established. 
Methods: We prospectively studied 105 patients with CHF due to an ischemic 
etiology (64%) or dilated cardiomyopathy (36%). All patients were in stable 
clinical condition and had full conventional medical therapy (mean age 
62+ly, NYHA class 2.6kO.1, BMI 24.7+0.5 kg/m’. LVEF 28+2%, peak VO, 
17.9+0.7 mlikglmin. Si was assessed from glucose and insulin dynamic 
profiles during an intravenous glucose tolerance test using the minlmal 
model technique. 
Results: During a mean follow-up period of 44*4 months, 53 (50%) patients 
died. Cumulative mortality was 20% at 24 months. In univariate Cox 
proportional hazard analysis, low Si predicted Increased mortality (RR 
1.21, p=O.O16). Also age, NYHA class, and peak VO, predicted mortality (all 
pcO.Ol), but LVEF and BMI did not. In multivariate analysis, low Si 
(p<O.Ol) preduzted increased mortality independently of age (pcO.O5), NYHA class 
and peak VO, (both p>O.Z). 
According to median Si (mm.‘.pU.mL-‘.I@), we divided the CHF patients in two 
groups. Patients with Si below median (n=52: mean Si 0.95*0.07 min.’ .pU.ml” .I04) 
had worse survival than patients with Si above median (n=53: mean Si 
4.08+0.40 min.‘.pU.mL-I.104): hazard ratio 2.7 [95% Cl 1.5-4.71, p<O.OlX). Both 
patient groups were similar for age and NYHA (both p>O.3), but patients 
with Si above median had higher LVEF (33*3 vs 24+2%) and peak V@ (19.9*1.0 
vs 16.8*1.0 mUkg/min; both ~~0.05). Patients with Si below median had 
P-year survival of 61% (46-741, but patients with Si above median had 
2-year survival of 63% [73-931 (hazard ratio adjusted for age, NYHA, LVEF. 
and peak VO,: 3.0 [1.5-6.01). 
Conclusion: In patients with CHF, impawed insulin 
sensitivity relates to poor survival, independently of established 
prognosticators. Therapeutically targeting impaired Insulin sensitivity may 
potentially improve prognosis in CHF patients. 
Emergency Depaltment. There were 1,586 patients in the study and 774 (47%) were 
diagnosed with HF. Of these, 634 (82%) had BMI data and were included for this analy- 
sis. 
Results: There was an inverse relationship between BNP levels and BMI in patients with 
HF (table). After accounting for age, sex, NYHA classification (I-IV) and history of HF by 
multiple linear regression analysis there remained a significant werse relationship 
between BNP and BMI ( r =-0.282, pc 0.0001). 
Conclusion: There is an inverse relationship between BNP levels and BMI in patients 
with HF. Improved prognosis m obese HF patients may be due to less ss~ere left ventric- 
ular dysfunction and hemodynamic abnonalities as indkxted by lower BNP concentra- 
tions. This finding may have diagnostic and/or therapeutic implications for obese patients 
with HF. 
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1061-60 Monocyte Chemoattractant Protein-l Plasma Level Is 
Elevated in Patients With Compensated lschemic 
Cardiomyopathy but Not the Tumor Necrosis Factor- 
Alpha 1061-76 Metabolic and Hemodynamic Parameters Do Not 
Predict Sleep Disordered Breathing in Severe Stable 
Heart Failure 
Laurie A. Kilkenny, Srinivas Murali. Guy A. MacGowan. Michael A. Math& Dennis M. 
McNamara, Tammy R. Tokarczyk, Rachel J. Givelber, Patrick J. Strollo, University of 
Pittsburgh, Pittsburgh, PA 
Background: Intermittent hypoxemia associated with sleep disordered breathing (SDB) 
contributes to cardiovascular impairment and may alter prognosis in heart failure (HF). 
We sought to examine the prevalence of SDB and assess whether hemodynamic and 
metabolic parameters would predict SDB I” stable severe HF patients (pts). 
Methods: We studied 22 pts (18M/4F; mean age 55.5 +/- 6.4 years; BMI 29.2+/-6) wth 
NYHA class Ill or IV HF (LVEF I9 +/- 0.05%) on optmal medical therapy (87% on ACE 
inhibitors. 91% on beta blockers) who underwent hemodynamic assessment, cardiopul- 
monary exercise study (modified Naughton protocol), and unattended cardiopulmonary 
slew studv (Stardust TM with nasal pressure). The presence of Central Sleep Apnea- ,~ 
Cheyne-Stokes Respirations (CSA-CSR) and Obstructive sleep dwxdered breathing 
(OSDB) was assessed using apnea hypopnea index, frequency of central and obstruc- 
twe events and duration of hypoxemia. The coefficient of determination (r2) was deter- 
mined by linear regression. 
Results Fifteen pts (68%) had ischemic cardiomyopathy; IO pts (45%) had Paroxysmal 
Nocturnal Dyspnea ; and 9 pts (41%) had Implantable defibrillators. Seven pts (32%) 
were diagnosed with CSA-CSR and I4 pts (64%) with OSDB. For the group. Desatura- 
tion event frequency was 22.4+/- 25.6; Apnea Hypopnea Index 30.9+/-16.7; and Minutes 
02 saturation <90% 42.6 +/- 100.9 minutes. Pulmonary artery wedge pressure (16.8 +/- 
7.2mm Hg); Cardiac Index (2.4 +I- 0.4 llminim2); PA mean pressure (28.3 +/- 11 mmHg); 
mlxed venous 02 saturation (66.2 +/- 5.4%); peak exercise oxygen consumption (16 +I- 
5.8 mllminlkg); and exercise ventilatory equivalent for carbon-dioxide (39.1+/- 11.3) did 
not correlate with the presence of SDB. 
Conclusions: 1) SDB is very common in pts with severe stable HF. 2) The prevalence of 
SDB in our series was 95% with a high proportion of OSDB. 3) No hemodynamic or met- 
abolic parameters correlated with the presence of SDB. 4) Stable severe HF pts should 
be routmely evaluated for the presence of SDB. 
1061-79 B-Type Natriuretic Peptide Levels Are Inversely Related 
to Body Mass Index in Patients With Heart Failure 
Brian J. Mundy, James McCord, Richard M. Nowak, Michael P. Hudson, Barabara 
Czerska, Gordon Jacobsen, Torbjorn Omland, Alan H. Wu, Phillippe Due, Judd E. 
Hollander, Peter A. McCullough, Alan S. Maisel, Henry Ford Hospital, Detroit, Ml 
Background: B-type natriurebc peptide (BNP) is a neurohormone secreted from the 
ventricular myocardium in response to increased wall tension, and is commonly elevated 
I” patients with heart failure (HF). BNP elevation has prognostic significance in patients 
with HF, and obese patients with HF are known to have a better prognosis for unclear 
reasons. We sought to determine the relationship, if any, between BNP levels and body 
mass index (BMI) in patients presenting to the Emergency Department with HF. 
Methods: The BNP Multinational Study was a seven center prospective study that eval- 
uated the diagnostic accuracy of BNP measurement for identifying patients with HF in the 
March 19,2003 
Samer J. Khouri, Jeanene Pohorence Ferguson, Laura Yamokoski, Karen Donavan, 
Amy Ferketich, Philip Binkley, Ohio State University, Columbus, OH, Medical College of 
Ohio, Toledo, OH 
Background: Several studies have shown that cytokine plasma levels are elevated in 
patients with decompensated heart failure. The treatment of these patients lead to 
decreased levels of Tumor necrosis Factor-alpha (TNF). A growing body of experimental 
evidence supports the pivotal role of chemokines in the pathogenesis of coronary artery 
disease and cardiomyopathy. The endothelial expression of monocyte chemoanractant 
protein-l (MCP-1) is apparently essential for the earliest cellular responses of atherogen- 
esis. We compared chemokine levels of MCP-I with cytokine levels of TNF in patients 
with compensated ischemic cardiomyopathy (NYHA functional class II & Ill) who were 
treated with B-blockers and ACE-Inhibitors for 3 months or more. 
Methods: MCP-I and TNF levels were obtained from 16 healthy controls and 21 patients 
with ischemic cardiomyopathy using commercially available immunoassays (R&D Sys- 
tem, Minneapolis, MN). The assays used the quantitative sandwich enzyme immunoas- 
say technique. Exact Wilcoxon Rank Sum’tests were performed to compare MCP-I and 
TNF levels between patients and healthy controls. The outcome variables were deter- 
mined from the average of two MCP-1 measurements and two TNF measurements. 
Two-sample nonparametric tests were performed. 
Results: The average MCP-I level among patients was (281.88 + 106.28 ng/ml), 
whereas it was (157.88 + 42.92 ng/ml) among controls (p c 0.00001). The average TNF 
levels among patients were (8.40 * 3.86 pglml) and (7.9 * 2.17 pgiml) among controls 
(NS). Conclusion: MCP-1 continues to be elevated in patients with compensated 
ischemic cardiomyopathy despite the treatments. This study supports previous reports 
that TNF concentration plasma levels in compensated cardiomyopathy will decrease with 
medical treatment. These findings also support the hypotheses that the inflammatory 
process continues despite heart failure treatment with B-blockers and ACE-Inhibitors. 
Therapeutic strategies that block MCP-1 in heart failure pabents provide hope of prevent- 
ing or reversing disease progression. 
1061-81 Redhced Pulmonary Clearance of Endothelin-1 in 
Patients With Congestive Heart Failure 
Cezar Staniloae, Jocelvn Dupuia Gilbert Gosselin. lhor Dyrda, Marc Bois. Jacques 
C&pew, Raoul Bonan, Michel White, Alexandre Caron. Montreal Heart Institute, 
Montreal, PQ, Canada 
Background. Endothelin-I (ET-l) levels are increased in patients wth CHF and are 
strong predictors of outcome. The pulmonary circulation plays a major role in the produc- 
tion and removal of ET-l. The endothellal ETB receptor mediates ET-1 clearance and 
causes vasodilation through the release of nitric oxide and prostacyclin. 
Methods. Twenty-five patients with CHF undergoing diagnostic catheterization were 
recruited. A single bolus indicator-dilution experiment was performed by injection into the 
RV outflow tract of a mixture containing 1251.ET-1 and Evans’ blue-labelled albumin, and 
simultaneous collection of timed samples above the aortic valve. Hemodynamic parame- 
ters, ET-1 levels and pulmonary ET-l kinetic data were correlated using a Pearson corre- 
lation matrix. 
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Results. Ejection fraction was 29+7% (mean&D), the pulmonary capillary wedge pres- 
sure was l&7 mmHg, left ventricular end-diastolic pressure was 22*6 mmHg and mean 
pulmonary artery pressure (mPAP) was 26~6 mmHg. Plasma ET-l levels were similar in 
pulmonary artery (0.931*0.71 fmol/ml) and aorta (0.906*0.6 fmol/ml. p=O.769) and did 
not correlate with mPAP (r-0.139, p&521). Single pass pulmonary ET-l extraction was 
reduced compared with histoncal controls (31*15% vs 47*2%, p<O.OOl), as was plaSma 
clearance of ET-1 (912+610 mllmin YS 1424+77 mllmin, p=O.Ol). Lung clearance 
inversely correlated with mPAP (r=-0.490. p=O.O14). 
Conclusions. Pulmonary ET-l clearance is reduced in relation with the severity of pulmo- 
nary hypertension (PHT) in patients with CHF. While it does not seem to contribute to the 
increase in plasma ET-l levels, this evidence for reduction in endothelial ETB receptor 
activity may contribute to the development of PHT. 
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1062-59 What Is in the Differential Diagnosis of a B-Type 
Natriuretic Peptide Level of 1,000 pg/ml? 
1061-82 Evaluation of Platelets in Heart Failure: Is Platelet 
Activity Related to Etiology, Functional Class, or 
Clinical Outcomes? 
Peter A. McCullouah, Richard M. Nowak. James McCord, Torbjorn Omland, Catherine 
W. Knudsen. Philipoe Due. Judd E. Hollander. Philippe Gabriel Step. Marie-Claude 
Aumont, Arne Wes;heim. Alan B. Storrow, William f: Abraham, S&ant Lamba, Alan H. 
Wu. Alan S. Maisel. BNP Multinational Studv Investiaators. William Beaumont HosDital. 
Paul A. Gurbel, Wendy A. Gatt~s. Sergey F. Fuzaylov, Laura Gaulden, Vie Hasselblad, 
Victor L. Serebruanv. ChristoDher M. O’Connor. Sinai Center for Thrombosis Research, 
Baltimore, MD, Duke University Medical Center, Durham, NC 
Objectives: We sought to determine whether platelet activity in patients with heart failure 
(HF) is related to an ischemic versus non-ischemic etiology, clinical disease severity or 
adverse clinical outcomes. Background: Platelets activity may affect outcome in patients 
with HF. A prospective evaluation of the relation of baseline platelet function to HF etiol- 
ogy, NYHA class, and clinical outcomes has not been previously reported. Methods: 
Ninety-sir consecutive ambulatory hearl failure outpatients with an EFc .40 and NYHA 
Class II-IV symptoms who presented to the Duke Heart Failure Clinic and fourteen 
healthy controls formed the study groups. Baseline characteristics were determined and 
blood was analyzed for thromboxane (TX) 82, 6-ksto PGFI, platslst contractile force, 
ADPlcollagen shear-induced closure time, whole blood aggregation (WBA) and CD 41, 
CD31, CD62p and CD51/CD61 by flow cytometry. Survival status and hospitalizations 
were determined in the heart failure patient cohort. Results: The median age was 65 
years (22% female, 64% Caucasian). An ischemic etiology was present in 61%. The pop- 
ulation has mild-moderate HF: NYHA class I (l%), II (41%), Ill (46%), and IV (12.5%) and 
severe ventricular dysfunction (median EF = .20). There were 39 clinical events ( 7 
deaths, 3 cardiac transplants, 29 other first hospitalizations) in 305 median days follow- 
up. Platelet activity, indicated by WBA with 5pmol ADP (p=.O4) and TX 82 (p=.Ol), was 
higher in HF patients. WBA was greater than 90” percentile in 22% of HF patients vs 7% 
of controls. Markers of platelet function did not differ between the ischemic and non- 
ischemic groups and was not affected by antecedent aspirin. There was no relation of 
NYHA class or the occurrence of events to platelet activity. Conclusion: Platelet activity 
is heightened in 22% of outpatients with stable heart failure symptoms and is not affected 
by antecedent aspirin therapy. The degree of platelet activation is similar in ischemic and 
non-ischemic HF and is not related to clinical disease severity. Current methods to 
assess platelet activation do not appear to predict outcome. 
1061-83 Uric Acid and Survival In Chronic Heart Failure: 
Validation and Application In Metabolic, Functional, and 
Hemodynamic Staging 
Stefan D. Anker, Wolfram Doshner. Mathias Rauchhaus, Christoph Knosalla, Roland 
Hetzer, Andrew J. Coats, NHLI London, London, United Kingdom, Charit& Medical 
School, Berlin, Gsrmany 
Background: Serum uric acid (UA) could be a valid prognostic marker and useful for 
metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF). 
Methods: We performed a series of 3 studies. For the initial derivation study, 112 CHF 
patients (age 59*12 y, peak oxygen consumption [VO,] 17f7 mL/kg/min) were recruited. 
We validated the prognostic value of UA in a second, independent study (n=l82). In a 
third study, we investigated the relationship between MFH score and the decission to list 
patients for heart transplantation (rx120). 
Results: In the derivation study (12.month mortality: 24%) the best mortality predicting 
UA cut-off (at 12 months) was 565 pmol/L (independently of age, peak VQ, LVEF, 
diuretic dose, sodium, creatinine, and urea: pcO.0001). In the validation study (12-month 
mortality: 15%). UA _2565ymol/L predicted mortality (hazard ratio 7.14, p<O.OOOl). 
In 16 patients (from both studies) with UA &65 pmol/L, LVEF X25%, and peak VQ >14 
mUkglmin(i.e. with MFH score 3), 12-month survival was lowest (31%), compared to 
patients with 2 (64%). 1 (77%). or no risk factor (98% , p<O.OOOl). Considering all 294 
CHF patients, we found a graded relationship between serum UA and mortality in CHF 
(pcO.0001). Patients with UA in the normal range (a00 ~ol/L) had the best survival (at 
12.months: 93%). compared to patients with UA between 401 and 600 vol/L (87%, RR 
1.76), patients with UA between 601 and 800 pmol/L (54%, RR 6.27), and patients with 
UA >800 wol/L (17%. RR 18.53). 
In an independent study, 51% of patients with MFH score 2 and 89% of patients with 
MFH score 3 were listed for transplantation. The positive predictive value of not being 
listed for heart transplantation with an MFH score O/l was 100%. 
Conclusions: High serum UA levels are a strong and independent marker of impaired 
prognosis in patients with moderate to severe CHF. The relationship between serum UA 
and survival in CHF is graded. MFH staging of CHF patients is feasible 
Royal Oak, MI, University of California, San Diego School of Medicine, Veterans Affairs 
Medical Center, San Diego, CA 
Introduction Recent, approved indications for blood B-type natriuretic peptide (BNP) for 
the diagnosis of congestive heart failure (CHF) and as a prognostic indicator in patients 
with acute coronary syndromes raise questions on how to interpret very high BNP val- 
ues. 
Methods The BNP Multinational Study was a seven-center prospective study of 1586 
patients presenting with acute dyspnea who had blinded BNP levels measured. The ref- 
erence standard for CHF was adjudicated by two independent cardiologists, also blinded 
to BNP results. 
Results A total of 264 subjects (mean age 70.4 years, 57.2% male) had BNP values on 
arrival to the ED of> 1000 pg/ml. Subjects had the following characteristics: prior history 
of CHF 62.1%, history of coronary heart disease 48.5%, hypertension 65.5%, and lung 
disease in 30.3%; physical exam: rales 69.7%, 53 18.9%, elevated jugular venous pres- 
sure 44.3%, hepatic congestion 24.6%, and peripheral edema 66.3%. Abnormal chest x- 
rays wers present in 90.5%. The final diagnoses are shown in the pie chart. Of those with 
pulmonary disease, all subjects had at least one sign of volume overload on physical 
exam. Other diseases in the differential included atrial fibrillation, acute cardiac ishemis.. 
and chronic renal failure. 
Conclusion A BNP level -> 1000 pglml indicates the presence of CHF in 93.2% of 
cases. In 6.8% of cases without CHF, other serious conditions are present suggesting 
cardiac pressure and or volume overload. 
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1062-60 The Prognostic Value of Inflammatory and 
Neurohumoral Activation in Patients With Chagas’ 
Heart Dlsease 
Victor S. Issa, Amilcar 0. Mocelin, Fernando Bacal, Guilherme V. Guimaraes, Edecio 
Cunha. Giovanni V. Belloni. Jose F. Ramires, Edimar A. Bocchi, Heart Institute (InCor)- 
University of Sao Paula Medical School, Sao Paul& Brazil 
Background. Inflammatory mediators are of paramount importance in heart failure. 
Despite experimental evidence that cytokines play a central role in Chagas’ disease, data 
in humans is scarce. We studied the pattern of inflammatory and neurohumoral response 
in patients with Chagas’ disease as compared to patients with idiopathic dilated cardi- 
omyopathy (IDC). 
Methods. We studied 35 patients with IDC (IDC group) and 28 patients with Chagas’ 
heart disease (CHAGAS group); we measured and compared plasma tumor necrosis 
factor alfa (TNF-a), soluble TNF-a receptor type l(sTNF-RI), soluble Fas (SF@, inter- 
leukin 6 (IL-6), and brain natriuretic peptide (BNP) concentrations in both groups; the 
association between the substances measured and clinical events (heart transplantation 
or death) was ascertained. Patients were stratified according to functional class and peak 
oxygen consumption (VOPmax). 
